Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q1 FY2025 Earnings Presentation
13 slides from Natco Pharma's earnings presentation, Aug 12, 2024
Slide 1: Exchange filing cover letter for Q1 FY25 Investor Presentation
12th August, 2024 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam, Sub: - Q1 FY25 I
Slide 2: Earnings Presentation Q1FY25
Earnings Presentation Q1FY25
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Table of Contents
Table of Contents 1 Q1FY25 Key Business & Consolidated Financial Highlights 2 Financial Summary 3 Product Portfolio & Pipeline Natco Pharma Limited – Earnings Presentation – Q1FY25
Slide 5: Q1FY25 Key Business & Consolidated Financial Highlights
1 Q1FY25 Key Business & Consolidated Financial Highlights Natco Pharma Limited – Earnings Presentation – Q1FY25
Slide 6: Q1FY25 – Key Business & Consolidated Financial Highlights
Q1FY25 – Key Business & Consolidated Financial Highlights Total Revenue stood at INR 14,107 mn| Pharma Export Formulations at INR 12,101 mn | Domestic Formulations Revenue at INR 1,022 mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 8,529 mn for Q1FY25 Profit after tax for
Slide 7: Q1FY25 – Quarterly Performance
Q1FY25 – Quarterly Performance Revenue Breakup (INR mn) Revenue Breakup (%) – Q1FY25 1% 3% 3% Revenue Division Q1FY25 Q1FY24 Q4FY24 7% API Revenue 392 751 500 Formulation Formulation – Exports (incl profit share, license income, export service income & 12,101 8,842 9,549 86% Subsidiaries) Export For
Slide 8: Financial Summary
2 Financial Summary Natco Pharma Limited – Earnings Presentation – Q1FY25
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Million) Q1FY25 Q1FY24 Q4FY24 Total Revenue 14,107 11,602 11,103 Total Expenses (before finance cost and depreciation) 5,578 6,125 5,710 Earnings before interest, tax, depreciation and amortization (EBITDA) 8,529 5,477 5,393 EBITDA Ma
Slide 10: Key Product Pipeline
3 Key Product Pipeline Natco Pharma Limited – Earnings Presentation – Q1FY25
Slide 11: Key Product Pipeline - USA
Key Product Pipeline - USA 28 Para IVs in the pipeline 13 Approved (either tentative or fully) Key Sole FTFs (Para IV) in the pipeline Key Para IV products in the pipeline Therapeutic Therapeutic Key Brand Molecule Segment / Primary Key Brand Molecule Segment / Primary Indication Indication Eliquis
Slide 12: Earnings Call Details – Q1FY25
Earnings Call Details – Q1FY25 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Director and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences will be held at 11 AM on 13/08/2024. Details
Slide 13: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546323 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma